The First Case of Pseudomonas aeruginosa Bacteremic Pneumonia in a Cancer Patient Receiving Pegfilgrastim

Intern Med. 2017;56(15):2039-2042. doi: 10.2169/internalmedicine.56.8245. Epub 2017 Aug 1.

Abstract

A single dose of pegfilgrastim or the daily administration of colony-stimulating factors can be used to prevent febrile neutropenia. This may delay the detection of rapidly progressive infections among cancer patients undergoing chemotherapy. We report a case of Pseudomonas aeruginosa bacteremic pneumonia that occurred in a patient receiving pegfilgrastim.

Keywords: Gram stain; Pseudomonas aeruginosa; bacteremic pneumonia; pegfilgrastim; solid cancer.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Bacteremia / diagnostic imaging
  • Bacteremia / drug therapy
  • Bacteremia / immunology
  • Filgrastim / adverse effects*
  • Filgrastim / therapeutic use
  • Humans
  • Immunocompromised Host
  • Male
  • Neutropenia / chemically induced
  • Neutropenia / prevention & control
  • Pancreatic Neoplasms / drug therapy
  • Pneumonia, Bacterial / diagnostic imaging*
  • Pneumonia, Bacterial / drug therapy
  • Pneumonia, Bacterial / immunology
  • Polyethylene Glycols / adverse effects*
  • Polyethylene Glycols / therapeutic use
  • Pseudomonas Infections / diagnostic imaging*
  • Pseudomonas Infections / drug therapy
  • Pseudomonas Infections / immunology
  • Radiography
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Tomography, X-Ray Computed

Substances

  • Anti-Bacterial Agents
  • Antineoplastic Agents
  • Recombinant Proteins
  • pegfilgrastim
  • Polyethylene Glycols
  • Filgrastim